Zenas BioPharma, Inc.
ZBIO
$16.93
$0.613.74%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 27.27% | 54.18% | 140.75% | 258.53% | 126.65% |
| Gross Profit | -27.27% | -10.02% | -116.27% | -182.49% | -126.65% |
| SG&A Expenses | 105.87% | 151.67% | 162.92% | 48.37% | 47.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.94% | 71.62% | 144.65% | 185.09% | 110.00% |
| Operating Income | -38.94% | -35.36% | -124.48% | -215.05% | -110.00% |
| Income Before Tax | -37.46% | -21.50% | -114.84% | -208.42% | -30.74% |
| Income Tax Expenses | -- | -- | 42.52% | -- | -- |
| Earnings from Continuing Operations | -37.51% | -20.77% | -113.95% | -208.42% | -30.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.51% | -20.77% | -113.95% | -208.42% | -30.74% |
| EBIT | -38.94% | -35.36% | -124.48% | -215.05% | -110.00% |
| EBITDA | -39.03% | -35.44% | -124.62% | -214.86% | -110.13% |
| EPS Basic | 94.85% | 95.51% | 92.13% | -307.18% | -1,409.45% |
| Normalized Basic EPS | 94.85% | 95.48% | 92.00% | -121.66% | -95.02% |
| EPS Diluted | 94.85% | 95.51% | 92.13% | -356.12% | -1,411.08% |
| Normalized Diluted EPS | 94.85% | 95.48% | 92.00% | -126.74% | -95.02% |
| Average Basic Shares Outstanding | 2,571.18% | 2,589.71% | 2,620.21% | 400.53% | 2.23% |
| Average Diluted Shares Outstanding | 2,571.18% | 2,589.71% | 2,620.21% | 305.48% | 2.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |